A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia

Br J Haematol. 2019 May;185(3):583-587. doi: 10.1111/bjh.15563. Epub 2018 Nov 19.
No abstract available

Keywords: Aurora B kinase; BI 811283; acute myeloid leukaemia; low-dose cytarabine; phase I.

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / pharmacokinetics
  • Aurora Kinase B / antagonists & inhibitors*
  • Aurora Kinase B / metabolism
  • Cytarabine / administration & dosage
  • Cytarabine / adverse effects
  • Cytarabine / pharmacokinetics
  • Female
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / enzymology
  • Male
  • Middle Aged
  • Neoplasm Proteins / antagonists & inhibitors*
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / pharmacokinetics

Substances

  • Neoplasm Proteins
  • Protein Kinase Inhibitors
  • Cytarabine
  • AURKB protein, human
  • Aurora Kinase B

Associated data

  • ClinicalTrials.gov/NCT00632749
  • EudraCT/2007‐005684‐00